Search

Displaying results 3741 - 3750 of 7502 in total
  1. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    The drug made it to phase III trials before abandoned due to increased stroke. … Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

  2. Drug

    Azidocillin

    go.drugbank.com/drugs/DB08795
    Experimental

    Azidocillin is a penicillin antibiotic similir to ampicillin.

  3. Drug

    Posizolid

    go.drugbank.com/drugs/DB04850
    Investigational

    no results were reported). … In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though

  4. Drug

    Ingenol mebutate

    go.drugbank.com/drugs/DB05013
    ApprovedWithdrawn

    Ingenol mebutate was approved by the FDA in January 2012, and it is marketed under the name Picato®. Picato gel is indicated for the topical treatment of actinic keratosis.

  5. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. … The Company determined that the program was not meeting their expected primary and exploratory objectives.

  6. Drug

    Col-118

    go.drugbank.com/drugs/DB05778
    Investigational

    It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue. … COL-118, a topical compound based on the SansRosa technology, for the treatment of redness associated with rosacea and other skin disorders.

  7. Drug

    Mirfentanil

    go.drugbank.com/drugs/DB09175
    Experimental

    At high doses, it exhibits analgesic activity which is not fully reversed by opioid antagonists, suggesting that the drug has both opioid and non-opioid mechanisms of action. … lower doses, it antagonizes the analgesic effects of alfentanil and substitutes for naloxone in morphine-treated monkeys; however, it also reverses naloxone-precipitated withdrawal in pigeons trained to

  8. Drug

    WP-1301

    go.drugbank.com/drugs/DB17702
    Experimental

    It binds to an MHC class II molecule and is recognized by a Factor VIII-specific T cell.[L46138]

  9. Drug

    XT-150

    go.drugbank.com/drugs/DB21756
    Investigational

    XT-150 is a locally injectable non-viral therapy expressing IL-10v, a proprietary modified variant of IL-10.[L52125] It is being developed by Xalud Therapeutics.

    Synonyms: non-viral human interleukin-10 (IL-10) variant (IL-10var) encoding plasmid deoxyribonucleic acid (pDNA)
  10. Drug

    Azelastine

    go.drugbank.com/drugs/DB00972
    ApprovedInvestigational

    [L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first granted FDA approval in 1996.

    Mixtures: N-S-4Categories: Histamine H1 Antagonists, Non-Sedating